US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NAYA BIOSCIENCES INC

2.20

0.0000

Volume:- -

Turnover:403.41K

Market Cap:1.47M

PE:-0.05

High:2.20

Open:2.20

Low:2.20

Close:2.20

52wk High:17.04

52wk Low:1.38

Shares:666.06K

Float Shares:600.80K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-45.6589

EPS(LYR):-15.3474

ROE:--

ROA:--

PB:-0.10

PE(LYR):-0.14

Loading ...

Overview Company News Filings

Naya Biosciences Announces Pricing of $9.5 Million Public Offering

THOMSON REUTERS

Naya Biosciences Files Prospectus Relates to Sale of up to 14.9 Mln Units -SEC Filing

THOMSON REUTERS

BRIEF-Naya Biosciences Announces Development Of NY-500

Naya Biosciences Inc - to Initiate Clinical Trials in Early 2026

THOMSON REUTERS

Naya Biosciences Announces Development of NY-500, a Novel AI-Optimized Pd-1 X Vegf Bifunctional Antibody

THOMSON REUTERS

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NAYA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAYA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAYA\",,,,,undefined,":{"symbol":"NAYA","market":"US","secType":"STK","nameCN":"NAYA BIOSCIENCES INC","latestPrice":2.2,"timestamp":1745611200000,"preClose":2.2,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":600800,"shares":666057,"eps":-45.658928,"marketStatus":"Not Yet Opened","change":0,"latestTime":"04-25 16:00:00 EDT","open":2.2,"high":2.2,"low":2.2,"amount":403407.84099,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-45.658928,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772614800000},"marketStatusCode":0,"symbolChange":{"newSymbol":"IVF","executeDate":"2025-04-28"},"adr":0,"exchange":"NASDAQ","adjPreClose":2.2,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAYA\",,,,,undefined,":{"symbol":"NAYA","floatShares":600800,"roa":"--","roe":"--","lyrEps":-15.347407,"shares":666057,"dividePrice":0,"high":2.2,"amplitude":0,"preClose":2.2,"low":2.2,"week52Low":1.38,"pbRate":"-0.10","week52High":17.04,"institutionHeld":0,"latestPrice":2.2,"eps":-45.658928,"divideRate":0,"volume":0,"delay":0,"ttmEps":-45.658928,"open":2.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAYA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-28","symbol":"NAYA","oldSymbol":"NAYA","defaultRemindTime":1745847000000,"newSymbol":"IVF","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1745812800000},{"market":"US","date":"2025-03-18","symbol":"NAYA","defaultRemindTime":1742304600000,"type":"split","dateTimestamp":1742270400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-11-19","symbol":"NAYA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731992400000,"reportTimeType":"post","actualEps":-0.42},{"market":"US","date":"2024-08-14","symbol":"NAYA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-0.62},{"market":"US","date":"2024-05-15","symbol":"NAYA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-0.42}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAYA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAYA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1737691200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAYA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAYA","date":"2025-04-25","current":-0.048183,"percent":0.736111,"low":-0.259061,"twenty":-0.217505,"median":-0.150617,"eighty":-0.084508,"high":-0.068368,"avg":-0.147176,"sd":0.056722,"marketCap":1352095},"quantilePoints":[{"date":"2025-01-10","current":-0.259061,"twenty":-0.259061,"median":-0.259061,"eighty":-0.259061,"marketCap":3849528},{"date":"2025-01-17","current":-0.12706,"twenty":-0.245023,"median":-0.150617,"eighty":-0.138567,"marketCap":1888059},{"date":"2025-01-24","current":-0.223181,"twenty":-0.244645,"median":-0.220534,"eighty":-0.148207,"marketCap":3316379},{"date":"2025-01-31","current":-0.231338,"twenty":-0.23398,"median":-0.221798,"eighty":-0.150617,"marketCap":3437581},{"date":"2025-02-07","current":-0.217505,"twenty":-0.229468,"median":-0.219675,"eighty":-0.204127,"marketCap":3232034},{"date":"2025-02-14","current":-0.171715,"twenty":-0.225147,"median":-0.219413,"eighty":-0.171715,"marketCap":2551606},{"date":"2025-02-21","current":-0.181254,"twenty":-0.223582,"median":-0.217505,"eighty":-0.171715,"marketCap":2693362},{"date":"2025-02-28","current":-0.176485,"twenty":-0.222351,"median":-0.197829,"eighty":-0.173088,"marketCap":2622484},{"date":"2025-03-07","current":-0.14777,"twenty":-0.220653,"median":-0.18135,"eighty":-0.169788,"marketCap":2195799},{"date":"2025-03-14","current":-0.15316,"twenty":-0.21989,"median":-0.178798,"eighty":-0.150941,"marketCap":2275891},{"date":"2025-03-21","current":-0.093012,"twenty":-0.219633,"median":-0.176962,"eighty":-0.147865,"marketCap":1382118},{"date":"2025-03-28","current":-0.094602,"twenty":-0.219447,"median":-0.175316,"eighty":-0.133964,"marketCap":1405744},{"date":"2025-04-04","current":-0.083472,"twenty":-0.219423,"median":-0.171715,"eighty":-0.098259,"marketCap":1240362},{"date":"2025-04-11","current":-0.068368,"twenty":-0.218497,"median":-0.160028,"eighty":-0.093966,"marketCap":1015916},{"date":"2025-04-17","current":-0.073138,"twenty":-0.217734,"median":-0.151896,"eighty":-0.09015,"marketCap":1086794},{"date":"2025-04-25","current":-0.090992,"twenty":-0.217505,"median":-0.150617,"eighty":-0.084508,"marketCap":1352095}],"updateTime":1772603753229},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAYA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503604300","title":"Naya Biosciences Announces Pricing of $9.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503604300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503604300?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:15","pubTimestamp":1736777744,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA89FLQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NAYA"],"gpt_icon":0},{"id":"2501633209","title":"Naya Biosciences Files Prospectus Relates to Sale of up to 14.9 Mln Units -SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2501633209","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501633209?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:22","pubTimestamp":1736256152,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O31H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NAYA"],"gpt_icon":0},{"id":"2501995258","title":"BRIEF-Naya Biosciences Announces Development Of NY-500","url":"https://stock-news.laohu8.com/highlight/detail?id=2501995258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501995258?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:47","pubTimestamp":1736174864,"startTime":"0","endTime":"0","summary":"Jan 6  - NAYA Biosciences Inc   :   * NAYA BIOSCIENCES ANNOUNCES DEVELOPMENT OF NY-500, A NOVEL AI-OPTIMIZED PD-1 X VEGF BIFUNCTIONAL ANTIBODY   * NAYA BIOSCIENCES INC - TO INITIATE CLINICAL TRIALS IN EARLY 2026   * NAYA BIOSCIENCES INC - NY-500 EXPECTED TO ENTER PHASE 1/2A TRIALS IN EARLY 2026   * NAYA BIOSCIENCES INC - PHASE 1/2A CLINICAL TRIALS EXPECTED TO START IN 2025Source text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAYA","BK4082"],"gpt_icon":1},{"id":"2501231092","title":"Naya Biosciences Inc - to Initiate Clinical Trials in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2501231092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501231092?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:30","pubTimestamp":1736170202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA99DVWN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAYA","BK4082"],"gpt_icon":0},{"id":"2501231018","title":"Naya Biosciences Announces Development of NY-500, a Novel AI-Optimized Pd-1 X Vegf Bifunctional Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2501231018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501231018?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:30","pubTimestamp":1736170202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA99DVWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NAYA"],"gpt_icon":0},{"id":"2501123442","title":"NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2501123442","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501123442?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:30","pubTimestamp":1736170200,"startTime":"0","endTime":"0","summary":" PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications  NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004621/0/en/NAYA-Biosciences-Announces-Development-of-NY-500-a-Novel-AI-Optimized-PD-1-x-VEGF-Bifunctional-Antibody.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4107","L","BK4588","HCC","BK4082","BK4023","BK4080","PD","BK4006","BK4231","SITC","LU0053666078.USD","LU1169590202.USD","NAYA","BK4585"],"gpt_icon":0},{"id":"2479316082","title":"NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479316082","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479316082?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:00","pubTimestamp":1730379600,"startTime":"0","endTime":"0","summary":"Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rateSARASOTA, Fla. and MIAMI, Oct.  31, 2024  (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2972674/0/en/NAYA-Biosciences-to-Present-Translational-Insights-to-Support-Phase-I-IIa-Clinical-Trials-for-its-GPC3-Targeting-NK-Engager-Bispecific-Antibody-at-the-2024-Annual-Meeting-of-the-So.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4006","IE00BYTNYN87.SGD","BK4231","SG9999011746.SGD","SITC","BK1541","BK1103","HCC","IE00B12V2V27.USD","BK4082","NAYA","IE00BYQNZ168.SGD","01308"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":30,"code":"91000000","status":"200"}]}}